These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 33379356

  • 1. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liao LZ, Chen CT, Li NC, Lin LC, Huang BS, Chang YH, Chow LP.
    Int J Mol Sci; 2020 Dec 28; 22(1):. PubMed ID: 33379356
    [Abstract] [Full Text] [Related]

  • 2. Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma.
    Liu T, Xie XL, Zhou X, Chen SX, Wang YJ, Shi LP, Chen SJ, Wang YJ, Wang SL, Zhang JN, Dou SY, Jiang XY, Cui RL, Jiang HQ.
    World J Gastroenterol; 2021 Jul 28; 27(28):4667-4686. PubMed ID: 34366628
    [Abstract] [Full Text] [Related]

  • 3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 28; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
    Liu C, Peng X, Li Y, Liu S, Hou R, Zhang Y, Zuo S, Liu Z, Luo R, Li L, Fang W.
    Biomed Pharmacother; 2020 Mar 28; 123():109780. PubMed ID: 31901550
    [Abstract] [Full Text] [Related]

  • 6. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway.
    Chao HM, Huang HX, Chang PH, Tseng KC, Miyajima A, Chern E.
    Oncotarget; 2017 Jan 10; 8(2):2604-2616. PubMed ID: 27911878
    [Abstract] [Full Text] [Related]

  • 7. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z.
    Biomed Pharmacother; 2017 Apr 10; 88():421-429. PubMed ID: 28122307
    [Abstract] [Full Text] [Related]

  • 8. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Apr 10; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 9. Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells.
    Zeng CM, Shao B, Chen YP, Ding GS.
    Curr Med Sci; 2024 Aug 10; 44(4):789-798. PubMed ID: 38926329
    [Abstract] [Full Text] [Related]

  • 10. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 11. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 09; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 12. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
    Wang H, Xu L, Zhu X, Wang P, Chi H, Meng Z.
    Oncol Rep; 2014 Oct 09; 32(4):1465-72. PubMed ID: 25070581
    [Abstract] [Full Text] [Related]

  • 13. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 14. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
    Suk FM, Liu CL, Hsu MH, Chuang YT, Wang JP, Liao YJ.
    Sci Rep; 2019 Nov 21; 9(1):17259. PubMed ID: 31754201
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression.
    Zhang H, Cheng S, Zhang M, Ma X, Zhang L, Wang Y, Rong R, Ma J, Xia S, Du M, Shi F, Wang J, Yang Q, Bai X, Leng J.
    Int J Oncol; 2014 Mar 21; 44(3):769-80. PubMed ID: 24378923
    [Abstract] [Full Text] [Related]

  • 16. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai MH, Liu HC, Zhang RY, Liu C.
    World J Gastroenterol; 2015 Jan 07; 21(1):196-213. PubMed ID: 25574092
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY, Hwang S, Moon KM, Won YJ, Song GW, Kim N, Tak E, Ryoo BY, Hong HN.
    Anticancer Res; 2015 Apr 07; 35(4):1967-76. PubMed ID: 25862849
    [Abstract] [Full Text] [Related]

  • 18. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.
    Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY, Mukhtar H.
    Oncotarget; 2014 May 15; 5(9):2462-74. PubMed ID: 24770864
    [Abstract] [Full Text] [Related]

  • 19. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y, Xu H, Li M, Wu H, Guo Y, Chen J, Shan J, Chen X, Shen J, Ma Q, Liu J, Wang M, Zhao W, Hong J, Qi Y, Yao C, Zhang Q, Yang Z, Qian C, Li J.
    Cancer Lett; 2019 Jul 10; 454():78-89. PubMed ID: 30980868
    [Abstract] [Full Text] [Related]

  • 20. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M.
    PLoS One; 2021 Jul 10; 16(9):e0256755. PubMed ID: 34473785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.